Basit öğe kaydını göster

Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.

dc.contributor.authorErturk, K
dc.contributor.authorTas, Faruk
dc.date.accessioned2021-03-02T19:43:33Z
dc.date.available2021-03-02T19:43:33Z
dc.identifier.citationTas F., Erturk K., "Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.", Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020
dc.identifier.issn1078-1552
dc.identifier.otherav_38374938-5fed-4be9-9694-d20877cd3100
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/5869
dc.identifier.urihttps://doi.org/10.1177/1078155220909426
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleSingle-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
dc.typeMakale
dc.relation.journalJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
dc.contributor.department, ,
dc.contributor.firstauthorID2195098


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster